# Melatonin, Soluble Urokinase-type Plasminogen Activator Receptor, and Orosomucoid 2 Levels in PPROM

> **NCT04588220** · — · UNKNOWN · sponsor: **Cengiz Gokcek Women's and Children's Hospital** · enrollment: 88 (estimated)

## Conditions studied

- Preterm Premature Rupture of Membranes

## Interventions

- **OTHER:** Obstetric ultrasound and fetal-maternal assessment

## Key facts

- **NCT ID:** NCT04588220
- **Lead sponsor:** Cengiz Gokcek Women's and Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-07
- **Primary completion:** 2021-10-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04588220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04588220, "Melatonin, Soluble Urokinase-type Plasminogen Activator Receptor, and Orosomucoid 2 Levels in PPROM". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04588220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*